Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-02-15 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT IN RELATION TO INDEPENDENT NON-EXECUTIVE DIRECTORS BEING PENALISED FOR MATTERS NOT RELATED TO THE COMPANY
Board/Management Information Classification · 95% confidence The document is an announcement regarding independent non-executive directors being penalised for matters unrelated to the company. It references regulatory bodies (CSRC, SSE) and disciplinary decisions but does not contain financial statements or detailed financial data. The document is relatively short (3758 characters) and serves as a disclosure of board/management related information, specifically about directors' penalties and their impact on the company. This fits the category of Board/Management Information (MANG).
2022-02-15 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED NEW DRUG APPROVAL OF CHINA'S FIRST IDH1 INHIBITOR TIBSOVO (IVOSIDENIB TABLETS) AS A NEW PRECISION THERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the approval of a new drug (TIBSOVO) by the National Medical Products Administration of China (NMPA). It details the drug's clinical efficacy, regulatory milestones, and company statements about the approval. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an announcement of a regulatory approval event rather than a financial report or management discussion. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The content fits best as a general regulatory announcement about a significant company event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-02-09 English
Monthly Returns
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 January 2022. It details movements in authorised/registered share capital, issued shares, share options, and confirms no new securities were issued during the month. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements and confirmations under listing rules. The document length is about 9,131 characters, and it contains detailed tabular data on share capital but no financial statements or management commentary. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about share capital movements and confirmations under exchange rules, not a capital/financing update or share issue announcement since no new shares were issued.
2022-02-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities for CStone Pharmaceuticals, including authorized share capital, issued shares, share options exercised, and confirmations related to share issuance. It is submitted to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The content focuses on share capital changes and share option exercises during the month ended 31 January 2022. This type of document is a regulatory filing reporting share capital movements and share option exercises, not a full financial report or earnings release. It does not contain financial statements or management discussion but is a formal regulatory disclosure of share capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2022-02-08 English
RESIGNATION OF SUPERVISOR
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a supervisor from the company's supervisory committee. It includes details about the resignation date, the individual's confirmation of no disagreements, and gratitude from the board. There are no financial statements, no mention of report attachments, or regulatory certifications. The content clearly relates to a change in the company's board or senior management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this management change, confirming the classification.
2022-01-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-01-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.